Co-Diagnostics, Inc. (CODX)
| Market Cap | 6.78M -52.6% |
| Revenue (ttm) | 721,386 -28.1% |
| Net Income | -47.06M |
| EPS | -19.36 |
| Shares Out | 6.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,088 |
| Open | 1.060 |
| Previous Close | 1.070 |
| Day's Range | 1.060 - 1.090 |
| 52-Week Range | 0.906 - 46.500 |
| Beta | 2.86 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In... [Read more]
Financial Performance
In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.
Financial StatementsNews
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory Pandemic SALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX...
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response. Co-Dx will join officials from the U.S. De...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Transcript: Status update
A new collaboration with ReadyGo Diagnostics aims to enable blood-based molecular testing, expanding the platform's reach to blood-borne pathogens and underserved regions. Automation has doubled cartridge production efficiency, supporting scalable manufacturing in India and beyond. Clinical studies for decentralized tuberculosis testing are nearing completion, with regulatory submissions planned.
Co-Diagnostics Slides: Status update
Co-Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2026.
Co-Diagnostics and ReadyGo Diagnostics announce collaboration program
Co-Diagnostics (CODX) and ReadyGo Diagnostics, a UK-based developer of field sample-preparation technology, announced that the companies are collaborating to evaluate the potential use of ReadyGo’s sa...
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of ...
Co-Diagnostics to hold a press conference
CEO Dwight Egan to hold a press conference in New York on September 16 at 10:30 am.Webcast Link
Co-Diagnostics to hold press conference on September 16
Co-Diagnostics (CODX) announced that it will host a press conference and live webcast Wednesday, September 16, at 10:30 a.m. Eastern Time. Co-Diagnostics CEO Dwight Egan will deliver a presentation fo...
Co-Diagnostics to Hold Press Conference
Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m.
Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
Two full laboratory installations completed in Florida; installation and customer training underway in Indiana State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics launches cloud, mobile infrastructure in India
Co-Diagnostics (CODX) announced the launch of its integrated cloud infrastructure in India. The deployment is intended to support the Company’s ongoing clinical studies for its point-of-care Mycobacte...
Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
Localized cloud environment is designed to support ongoing clinical studies and establish the digital foundation for future data commercialization strategies SALT LAKE CITY, Sept. 3, 2026 /PRNewswire/...
Co-Diagnostics announces first international deployment of Vector Smart
Co-Diagnostics (CODX) announced the first international deployment of its Vector Smart mosquito surveillance platform, to include shipments of laboratory equipment, consumables, and other mosquito aba...
Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line SALT LAKE CITY, Sept. 1, 2026 /PRNew...
Co-Diagnostics files to sell 3.4M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.4M shares of common stock. The company is not selling any…
Co-Diagnostics Registration statement: Registration filing
Co-Diagnostics filed a registration statement on August 24, 2026, providing details about a securities offering with the SEC.
Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Dia...
Co-Diagnostics Earnings Call Transcript: Q2 2026
Q2 2026 saw progress in regulatory and clinical milestones, including FDA submission for the Flu A/B & RSV assay and advancement of the TB program in India. Revenue remained modest, but operating losses narrowed due to disciplined expense management. Commercialization and global expansion remain key priorities.
Co-Diagnostics Earnings release: Q2 2026
Co-Diagnostics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Co-Diagnostics Quarterly report: Q2 2026
Co-Diagnostics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Co-Diagnostics Reports Second Quarter 2026 Financial Results
Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity a...
Co-Diagnostics submits FDA 510(k) premarket notification for Co-Dx PCR Flu test
Co-Diagnostics (CODX) announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. FDA for the Co-Dx PCR Flu A/B &…